Atty. Dkt. No.: 8325-0012 Client Dkt. No.: S12-US1

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior listings and versions:

- 1. (currently amended): A method for binding an exogenous molecule to a binding site, wherein the binding site <u>comprises a target site is</u> located within a region of interest in cellular chromatin, wherein the method comprises:
 - (a) identifying an accessible region within the region of interest;
- (b) identifying a target site for the exogenous molecule within the accessible region; and
 - (c) introducing the exogenous molecule into the cell; whereby the exogenous molecule binds to the binding site.
- 2. (withdrawn): The method according to claim 1 wherein the cellular chromatin is in a chromosome.
- 3. (withdrawn): The method according to claim 1 wherein the accessible region is a nuclease hypersensitive region.
 - 4 to 5. (canceled).
- 6. (withdrawn): The method according to claim 1, wherein the exogenous molecule is a protein.
- 7. (withdrawn): The method according to claim 6 wherein the protein performs a process selected from the group consisting of replication, recombination, integration, DNA repair, transcriptional regulation and chromatin remodeling.
- 8. (withdrawn): The method according to claim 6 wherein the protein is used for detection of a target sequence.
- 9. (withdrawn): The method according to claim 7, wherein the protein is a transcription factor.

Atty. Dkt. No.: 8325-0012

Client Dkt. No.: S12-US1

10. (withdrawn): The method according to claim 9, wherein the transcription factor is a zinc finger protein (ZFP).

- 11. (withdrawn): The method according to claim 6 wherein the protein is encoded by an exogenous nucleic acid introduced into the cell.
 - 12. (withdrawn): The method according to claim 1, wherein the cell is a eukaryotic cell.
 - 13. (withdrawn): The method according to claim 12, wherein the cell is a plant cell.
- 14. (withdrawn): The method according to claim 12, wherein the cell is a mammalian cell.
 - 15. (withdrawn): The method according to claim 14, wherein the cell is a human cell.
- 16. (withdrawn): The method according to claim 1, wherein the binding site is in a coding region.
- 17. (withdrawn): The method according to claim 1, wherein the binding site is in a non-coding region.
- 18. (withdrawn): The method according to claim 10, wherein the binding site comprises the sequence 5'-NNx aNy bNz c-3', wherein

each of (x,a), (y,b) and (z,c) is (N,N) or (G,K); and

at least one of (x,a), (y,b) and (z,c) is (G,K); wherein N is any nucleotide and K is either G or T.

- 19. (canceled).
- 20. (withdrawn): The method according to claim 11 wherein the nucleic acid is introduced into the cell by a method selected from the group consisting of lipid-mediated gene transfer, electroporation, direct injection, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran mediated transfer, and viral vector-mediated transfer.

USSN: 09/844,662 Atty. Dkt. No.: 8325-0012

Client Dkt. No.: S12-US1

21. (currently amended): A method for binding a ZFP transcription factor to a binding site, wherein the binding site comprises a target site is located within a region of interest in cellular chromatin, wherein the method comprises:

- (a) identifying an accessible region within the region of interest;
- (b) identifying a zinc finger protein (ZFP) binding sequence within the accessible region;
- (c) designing a ZFP to bind to the binding sequence; and
- (d) introducing the ZFP into the cell; whereby the ZFP binds to the binding site.
- 22. (withdrawn): The method according to claim 21 wherein the ZFP is introduced into the cell by introducing a DNA construct encoding the ZFP into the cell under conditions in which the construct expresses the ZFP.
- 23. (withdrawn): The method according to claim 21 wherein the cellular chromatin is in a chromosome.
- 24. (withdrawn): The method according to claim 21 wherein the accessible region is a nuclease hypersensitive region.

25 to 26. (canceled).

27. (withdrawn): The method according claim 21, wherein the binding site comprises the sequence 5'-NNx aNy bNz c-3', wherein

each of (x,a), (y,b) and (z,c) is (N,N) or (G,K); and

at least one of (x,a), (y,b) and (z,c) is (G,K); wherein N is any nucleotide and K is either G or T.

28 to 56. (canceled).

57. (currently amended): A complex between an exogenous molecule and a binding site in cellular chromatin, wherein the binding site <u>comprises a target site and</u> is in an accessible region of cellular chromatin.

Atty. Dkt. No.: 8325-0012

Client Dkt. No.: S12-US1

58. (withdrawn): The complex of claim 57, wherein the exogenous molecule is a nucleic acid.

- 59. (withdrawn): The complex of claim 58, wherein the nucleic acid is a triplex-forming nucleic acid.
- 60. (previously presented): The complex of claim 57, wherein the exogenous molecule binds in the minor groove of double-stranded DNA.
- 61. (withdrawn): The complex of claim 57, wherein the exogenous molecule is a small molecule therapeutic.
- 62. (previously presented): The complex of claim 57, wherein the exogenous molecule is a protein.
- 63. (previously presented): The complex of claim 62, wherein the protein is a transcription factor.
- 64. (previously presented): The complex of claim 63, wherein the transcription factor is a zinc finger protein (ZFP).
- 65. (previously presented): The complex of claim 57, wherein the accessible region is a nuclease hypersensitive region.
 - 66. (previously presented): A cell comprising the complex of claim 57.
- 67. (previously presented): The cell of claim 66, wherein the exogenous molecule is a protein.
- 68. (previously presented): The cell of claim 67, wherein the protein is encoded by a nucleic acid introduced into the cell.
 - 69. (previously presented): The cell of claim 66, wherein the cell is a plant cell.

Atty. Dkt. No.: 8325-0012

Client Dkt. No.: S12-US1

70. (previously presented): The cell of claim 66, wherein the cell is an animal cell.

71. (previously presented): The cell of claim 66, wherein the cell is a human cell.

72. (currently amended): A method for modulating the transcription of a gene in a cell,

wherein the gene is present in a chromosome of the cell, by binding an exogenous molecule to a

binding site in the chromosome, wherein the binding site comprises a target site in an accessible

region of cellular chromatin.

73. (withdrawn): The method of claim 73, wherein modulation comprises an increase in

transcription.

74. (withdrawn): The method of claim 72, wherein modulation comprises a decrease in

transcription.

75. (withdrawn): The method of claim 72, wherein the exogenous molecule is a nucleic

acid.

76. (withdrawn): The method of claim 72, wherein the nucleic acid is a triplex-forming

nucleic acid.

77. (withdrawn): The method of claim 72, wherein the exogenous molecule binds in the

minor groove of double-stranded DNA.

78. (withdrawn): The method of claim 72, wherein the exogenous molecule is a small

molecule therapeutic.

79. (withdrawn): The method of claim 72, wherein the exogenous molecule is a protein.

80. (withdrawn): The method of claim 79, wherein the protein is a transcription factor.

81. (withdrawn): The method of claim 80, wherein the transcription factor is a zinc

7

Atty. Dkt. No.: 8325-0012 Client Dkt. No.: S12-US1

finger protein (ZFP).

82. (withdrawn): The method of claim 72, wherein the accessible region is a nuclease hypersensitive region.

83. (withdrawn): The method of claim 79, wherein the protein is encoded by a nucleic acid introduced into the cell.

84. (withdrawn): The method of claim 72, wherein the cell is a plant cell.

85. (withdrawn): The method of claim 72, wherein the cell is an animal cell.

86. (withdrawn): The method of claim 72, wherein the cell is a human cell.